|
MechanismBacterial DNA gyrase inhibitors [+2] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.DE |
First Approval Date28 May 2020 |
100 Clinical Results associated with Tubilux Pharma SpA
0 Patents (Medical) associated with Tubilux Pharma SpA
100 Deals associated with Tubilux Pharma SpA
100 Translational Medicine associated with Tubilux Pharma SpA